Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Bipolar Disorder
and you are
between 18 and 65
years old
The primary goal of this phase is to monitor the long-term effects.
The treatment is already on the market.
Show me locations

The purpose

Converging evidence suggests that patients with bipolar disorder suffer from deficits in neurocognitive functioning that persist, despite remission of acute affective symptoms. These impairments contribute directly to functional disability, highlighting the need for interventions above and beyond standard treatments in order to achieve a full inter-episode recovery. The current study aims to investigate the safety and efficacy of a dopamine agonist (pramipexole), on these persistent cognitive abnormalities in euthymic bipolar patients using a placebo-controlled, adjunctive, 12-week trial design.

Provided treatments

  • Drug: Pramipexole
  • Drug: Placebo
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02397837. The sponsor of the trial is Brigham and Women's Hospital and it is looking for 100 volunteers for the current phase.
Official trial title:
Pramipexole in Bipolar Disorder: Targeting Cognition (PRAM-BD)